ATS Corp /ATS (ATS) Stock Analysis and Metrics

Ats

NYSE: ATS

$26.39 ▼ -0.11 (-0.42%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.59 Bn

P/E50.25

P/S1.21

Div. Yield0.13

ROIC (Qtr)0.00

Total Debt (Qtr)929.54 Mn

Revenue Growth (1y) (Qtr)36.13

Add ratio to table…

About

ATS Corporation delivers custom automation solutions to manufacturers seeking to increase throughput lower costs accelerate delivery and improve quality. The company serves customers in life sciences food and beverage consumer products transportation and energy markets. ATS engages in both green field projects such as equipping new factories and brown field projects including capacity expansions equipment upgrades and process optimizations. In addition to custom systems the company offers standard automation products platforms software and digital solutions and aftermarket service agreements.

Revenue is generated from the sale of custom automation systems standard automation products and related services including engineering design integration installation validation and post sale support. The company also provides software and digital solutions such as connected factory floor monitoring and data analytics. Contract values for individual systems often exceed one million dollars with some enterprise programs surpassing ten million dollars. Typical project durations range from six to twelve months while larger engagements may extend to eighteen to twenty four months or longer. Service agreements can exceed one million dollars and may span several years. In fiscal 2025 no single customer accounted for more than fifteen percent of total consolidated revenue.

The company operates through the following segments: Life Sciences Food and Beverage Consumer Products Transportation and Energy.

• Life Sciences provides automation solutions for high performance medical devices hand held and on body monitoring devices assay and chip assembly for reliable test results general pharmaceuticals and radiopharmaceuticals and large and small scale pharmacy and laboratory operations.

• Food and Beverage offers automation for food processing and packaging fresh food inspection convenience food preparation beverage filling technologies optical sorting X ray and vision inspection high speed and high precision packaging applications.

• Consumer Products supplies automation for production and packaging of personal care items cosmetics and household goods and technologies that support warehouse automation and distribution for retail and ecommerce channels.

• Transportation delivers automation for assembly and testing of automotive components with a focus on electric vehicle battery modules and packs motors rotors and axles to streamline material handling assembly workflows and testing.

• Energy addresses nuclear solar and other green energy applications supporting CANDU reactor commissioning refurbishment maintenance and decommissioning small modular reactors and large scale nuclear reactors while also providing automation for stationary fuel cells and oil and gas operations.

ATS Corporation holds a strong position in the automation industry due to its global footprint technical expertise and broad product and technology portfolio. The company operates in over eighty five locations across North America Europe Asia and other regions enabling localized service for multinational customers. Its workforce includes approximately two thousand two hundred engineers and four hundred program management personnel providing deep knowledge across diverse industrial markets. ATS emphasizes regulated industries where quality and reliability are mandatory giving it an advantage over competitors with narrower geographic or sector focus. The company’s competitive strengths include scale critical mass a full lifecycle service platform and the ability to de risk customer supply chains through automation.

The company serves manufacturers in the life sciences food and beverage consumer products transportation and energy sectors including firms that produce medical devices pharmaceuticals packaged foods personal care goods automotive components and energy equipment. While specific customer names are not disclosed in the filing ATS notes that no single customer represented more than fifteen percent of revenue in fiscal 2025.

Investment Thesis

▲ Bull case

ATS is strategically repositioning its portfolio away from low-margin, cyclical transportation projects toward higher-margin, regulated end markets like Life Sciences and Energy, where long-term structural demand is strengthening. The company has successfully exited large-scale automotive projects and is redeploying engineering and digital capabilities into higher-value niches such as end-of-life tire recycling and nuclear life-extension programs, which offer superior return profiles and less cyclicality. This strategic pivot is already reflected in the backlog, where Life Sciences and Energy now comprise nearly 80% of the $2 billion backlog heading into fiscal '27, up from a more diversified but lower-margin mix in prior years. The shift is not merely tactical but structural, aligning ATS with secular trends in radiopharmaceutical manufacturing, nuclear life extension, and automated lab systems — all areas where ATS’s engineering precision and digital twin capabilities create defensible, high-margin opportunities. Management’s explicit focus on increasing aftermarket revenue mix and improving asset utilization through digital twin integration further enhances revenue predictability and margin expansion potential, which the market may be underestimating as a near-term drag from transportation exit masks underlying quality improvement.
ATS’s Life Sciences segment is positioned to benefit from multiple overlapping secular tailwinds that are underappreciated by the market, particularly in radiopharmaceuticals and lab automation. The company’s Flex-Line sterile pharmaceutical production platform integrates critical manufacturing steps into a single solution, directly addressing customer pain points around process complexity and time-to-market for high-value therapies like targeted radiopharmaceuticals and GLP-1 auto-injectors. As isotope production capacity expands and targeted therapies broaden across oncology, cardiovascular, and neurological indications, demand for specialized, scalable infrastructure will accelerate — areas where ATS’s engineering depth and digital twin capabilities provide a defensible moat. Management explicitly noted that the Life Sciences funnel is broadening beyond single-program dependencies into mail-order pharmacy, automated visual inspection, and lab automation, reducing reliance on any single program like GLP-1 auto-injectors and creating a more resilient, diversified growth engine. This diversification, combined with expanding isotope supply and broadening therapeutic applications, suggests Life Sciences growth is not merely recovering from a GLP-1-driven peak but entering a multi-year expansion phase that the market may be underestimating due to near-term backlog moderation in one subsegment.
ATS’s capital allocation discipline and balance sheet strength are underappreciated catalysts for future value creation, particularly as the company transitions from restructuring to growth-oriented capital deployment. With leverage now at 2.8x net debt to adjusted EBITDA — within the target range of 2x to 3x — and working capital efficiency improving (non-cash working capital at 12.1% of revenues, down sequentially and below the 15% target), ATS has achieved the financial flexibility to pursue acquisitions without overleveraging. Management explicitly stated they are evaluating acquisitions based on industrial logic — seeking targets that enhance margin profile, boost aftermarket mix, and extend technical capabilities into adjacent applications — rather than chasing arbitrary valuation multiples. This disciplined approach, combined with a stated willingness to temporarily exceed leverage targets for high-return opportunities, positions ATS to pursue accretive deals in high-growth adjacencies like nuclear waste management, SMR fuel handling, or radiopharmacy automation — areas where its engineering expertise and digital tools offer unique differentiation. The market may be overlooking this latent M&A potential, focusing instead on near-term restructuring costs, while overlooking the company’s growing capacity to deploy capital toward higher-return, structurally advantaged opportunities that could meaningfully accelerate long-term free cash flow generation and margin expansion toward the 15% target.

ATS is strategically repositioning its portfolio away from low-margin, cyclical transportation projects toward higher-margin, regulated end markets like Life Sciences and Energy, where long-term structural demand is strengthening. The company has successfully exited large-scale automotive projects and is redeploying engineering and digital capabilities into higher-value niches such as end-of-life tire recycling and nuclear life-extension programs, which offer superior return profiles and less cyclicality. This strategic pivot is already reflected in the backlog, where Life Sciences and Energy now comprise nearly 80% of the $2 billion backlog heading into fiscal '27, up from a more diversified but lower-margin mix in prior years. The shift is not merely tactical but structural, aligning ATS with secular trends in radiopharmaceutical manufacturing, nuclear life extension, and automated lab systems — all areas where ATS’s engineering precision and digital twin capabilities create defensible, high-margin opportunities. Management’s explicit focus on increasing aftermarket revenue mix and improving asset utilization through digital twin integration further enhances revenue predictability and margin expansion potential, which the market may be underestimating as a near-term drag from transportation exit masks underlying quality improvement.
ATS’s Life Sciences segment is positioned to benefit from multiple overlapping secular tailwinds that are underappreciated by the market, particularly in radiopharmaceuticals and lab automation. The company’s Flex-Line sterile pharmaceutical production platform integrates critical manufacturing steps into a single solution, directly addressing customer pain points around process complexity and time-to-market for high-value therapies like targeted radiopharmaceuticals and GLP-1 auto-injectors. As isotope production capacity expands and targeted therapies broaden across oncology, cardiovascular, and neurological indications, demand for specialized, scalable infrastructure will accelerate — areas where ATS’s engineering depth and digital twin capabilities provide a defensible moat. Management explicitly noted that the Life Sciences funnel is broadening beyond single-program dependencies into mail-order pharmacy, automated visual inspection, and lab automation, reducing reliance on any single program like GLP-1 auto-injectors and creating a more resilient, diversified growth engine. This diversification, combined with expanding isotope supply and broadening therapeutic applications, suggests Life Sciences growth is not merely recovering from a GLP-1-driven peak but entering a multi-year expansion phase that the market may be underestimating due to near-term backlog moderation in one subsegment.
ATS’s capital allocation discipline and balance sheet strength are underappreciated catalysts for future value creation, particularly as the company transitions from restructuring to growth-oriented capital deployment. With leverage now at 2.8x net debt to adjusted EBITDA — within the target range of 2x to 3x — and working capital efficiency improving (non-cash working capital at 12.1% of revenues, down sequentially and below the 15% target), ATS has achieved the financial flexibility to pursue acquisitions without overleveraging. Management explicitly stated they are evaluating acquisitions based on industrial logic — seeking targets that enhance margin profile, boost aftermarket mix, and extend technical capabilities into adjacent applications — rather than chasing arbitrary valuation multiples. This disciplined approach, combined with a stated willingness to temporarily exceed leverage targets for high-return opportunities, positions ATS to pursue accretive deals in high-growth adjacencies like nuclear waste management, SMR fuel handling, or radiopharmacy automation — areas where its engineering expertise and digital tools offer unique differentiation. The market may be overlooking this latent M&A potential, focusing instead on near-term restructuring costs, while overlooking the company’s growing capacity to deploy capital toward higher-return, structurally advantaged opportunities that could meaningfully accelerate long-term free cash flow generation and margin expansion toward the 15% target.

▼ Bear case

ATS’s strategic exit from transportation, while framed as a margin-enhancing move, risks eroding a significant revenue base without guaranteed replacement growth in higher-margin segments, creating a near-term revenue gap that may not be fully offset by growth in Life Sciences and Energy. The company explicitly acknowledged removing approximately $50 million in dilutive transportation revenues, yet provided no clear timeline or quantifiable roadmap for replacing this volume with equivalent or higher-margin business in Life Sciences, Energy, or Consumer Products. While Life Sciences backlog remains strong at $1.1 billion (55% of total), management admitted that the Life Sciences funnel is experiencing “moderations in timing” in certain submarkets, including GLP-1 auto-injectors — a segment they previously cited as 20% of Life Sciences backlog. The broadening of the Life Sciences funnel into mail-order pharmacy and lab automation is presented as a mitigant, but no concrete timelines, customer commitments, or revenue ramp timelines were provided to substantiate that these adjacent areas will meaningfully offset the GLP-1-related backlog decline in the near term. Without clear visibility on when and how these new applications will convert to booked orders and revenue, the market may be overestimating the speed and scale of the transition away from transportation, leaving ATS vulnerable to a near-term revenue shortfall that could pressure margins before restructuring benefits fully materialize.
ATS’s margin expansion targets are overly optimistic given the persistent headwinds from SG&A inflation, foreign exchange headwinds, and the dilutive impact of restructuring costs, which may offset gains from aftermarket mix and asset utilization improvements. While management targets 50–75 basis points of adjusted EBITDA margin improvement in fiscal ’27, they acknowledged that SG&A expenses rose $5.6 million year-over-year in Q4 due to foreign exchange translation and higher professional fees — trends that are unlikely to reverse given the company’s global footprint and ongoing need for external expertise in complex projects like nuclear refurbishment and radiopharma infrastructure. Furthermore, the company expects $5–10 million in additional restructuring costs beyond Q1, alongside ongoing investments in CapEx and intangibles ($70–90 million range for FY27), which will continue to pressure earnings. The company’s plan to reinvest a portion of restructuring savings into growth areas like nuclear and radiopharma implies that near-term margin gains will be partially offset by reinvestment, making the 50–75 bps improvement target contingent on flawless execution — a risky assumption given the concurrent challenges of integrating aftermarket services into operating units, managing foreign exchange volatility, and executing multiple restructuring streams simultaneously. The market may be assuming margin expansion is imminent and linear, when in reality it will be uneven, delayed, and potentially undermined by persistent cost pressures.
ATS’s reliance on backlog conversion for near-term revenue visibility masks underlying weakness in new order generation, as evidenced by declining bookings and a book-to-bill ratio below 1.0, raising concerns about the sustainability of its current growth trajectory despite a seemingly strong backlog. The company reported Q4 order bookings of $704 million, down 18.4% year-over-year, with a trailing 12-month book-to-bill ratio of 0.99:1 — indicating that revenue is being recognized faster than new orders are being booked. While management attributes the Q4 booking decline to the lapping of large enterprise orders from the prior year, they offered no evidence of a recovery in booking momentum across key segments, instead emphasizing funnel health and backlog conversion. The Life Sciences funnel, while described as “broadening,” lacks specific metrics on conversion rates or deal velocity in emerging areas like mail-order pharmacy or lab automation, leaving unanswered whether these areas are generating meaningful new order flow or merely replacing declining GLP-1-related bookings. Similarly, while Energy backlog grew 40% year-on-year, driven by nuclear refurbishment and life extension, the company acknowledged that this growth is tied to specific, long-cycle programs with inherent timing lumpiness — meaning the strong backlog may not reflect sustainable, recurring demand. Without clear evidence of accelerating new order intake across core segments, the current backlog may represent a temporary high-water mark rather than a foundation for sustained growth, leaving the company vulnerable to a sharp revenue decline once the existing backlog is converted — a risk the market may be underestimating by focusing too heavily on backlog levels rather than booking trends.

ATS’s strategic exit from transportation, while framed as a margin-enhancing move, risks eroding a significant revenue base without guaranteed replacement growth in higher-margin segments, creating a near-term revenue gap that may not be fully offset by growth in Life Sciences and Energy. The company explicitly acknowledged removing approximately $50 million in dilutive transportation revenues, yet provided no clear timeline or quantifiable roadmap for replacing this volume with equivalent or higher-margin business in Life Sciences, Energy, or Consumer Products. While Life Sciences backlog remains strong at $1.1 billion (55% of total), management admitted that the Life Sciences funnel is experiencing “moderations in timing” in certain submarkets, including GLP-1 auto-injectors — a segment they previously cited as 20% of Life Sciences backlog. The broadening of the Life Sciences funnel into mail-order pharmacy and lab automation is presented as a mitigant, but no concrete timelines, customer commitments, or revenue ramp timelines were provided to substantiate that these adjacent areas will meaningfully offset the GLP-1-related backlog decline in the near term. Without clear visibility on when and how these new applications will convert to booked orders and revenue, the market may be overestimating the speed and scale of the transition away from transportation, leaving ATS vulnerable to a near-term revenue shortfall that could pressure margins before restructuring benefits fully materialize.
ATS’s margin expansion targets are overly optimistic given the persistent headwinds from SG&A inflation, foreign exchange headwinds, and the dilutive impact of restructuring costs, which may offset gains from aftermarket mix and asset utilization improvements. While management targets 50–75 basis points of adjusted EBITDA margin improvement in fiscal ’27, they acknowledged that SG&A expenses rose $5.6 million year-over-year in Q4 due to foreign exchange translation and higher professional fees — trends that are unlikely to reverse given the company’s global footprint and ongoing need for external expertise in complex projects like nuclear refurbishment and radiopharma infrastructure. Furthermore, the company expects $5–10 million in additional restructuring costs beyond Q1, alongside ongoing investments in CapEx and intangibles ($70–90 million range for FY27), which will continue to pressure earnings. The company’s plan to reinvest a portion of restructuring savings into growth areas like nuclear and radiopharma implies that near-term margin gains will be partially offset by reinvestment, making the 50–75 bps improvement target contingent on flawless execution — a risky assumption given the concurrent challenges of integrating aftermarket services into operating units, managing foreign exchange volatility, and executing multiple restructuring streams simultaneously. The market may be assuming margin expansion is imminent and linear, when in reality it will be uneven, delayed, and potentially undermined by persistent cost pressures.
ATS’s reliance on backlog conversion for near-term revenue visibility masks underlying weakness in new order generation, as evidenced by declining bookings and a book-to-bill ratio below 1.0, raising concerns about the sustainability of its current growth trajectory despite a seemingly strong backlog. The company reported Q4 order bookings of $704 million, down 18.4% year-over-year, with a trailing 12-month book-to-bill ratio of 0.99:1 — indicating that revenue is being recognized faster than new orders are being booked. While management attributes the Q4 booking decline to the lapping of large enterprise orders from the prior year, they offered no evidence of a recovery in booking momentum across key segments, instead emphasizing funnel health and backlog conversion. The Life Sciences funnel, while described as “broadening,” lacks specific metrics on conversion rates or deal velocity in emerging areas like mail-order pharmacy or lab automation, leaving unanswered whether these areas are generating meaningful new order flow or merely replacing declining GLP-1-related bookings. Similarly, while Energy backlog grew 40% year-on-year, driven by nuclear refurbishment and life extension, the company acknowledged that this growth is tied to specific, long-cycle programs with inherent timing lumpiness — meaning the strong backlog may not reflect sustainable, recurring demand. Without clear evidence of accelerating new order intake across core segments, the current backlog may represent a temporary high-water mark rather than a foundation for sustained growth, leaving the company vulnerable to a sharp revenue decline once the existing backlog is converted — a risk the market may be underestimating by focusing too heavily on backlog levels rather than booking trends.

Markets of customers [axis] Breakdown of Revenue (2026)

Peer Comparison

Companies in the Specialty Industrial Machinery

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEV	GE Vernova Inc.	270.93 Bn	28.46	6.55	2.79 Bn
2	ETN	Eaton Corp plc	156.55 Bn	39.19	5.50	21.05 Bn
3	PH	Parker-Hannifin Corp	124.04 Bn	35.64	5.91	9.58 Bn
4	CMI	Cummins Inc	91.66 Bn	34.29	2.70	6.89 Bn
5	EMR	Emerson Electric Co	82.90 Bn	67.34	4.53	13.36 Bn
6	ITW	Illinois Tool Works Inc	81.54 Bn	26.02	5.03	9.15 Bn
7	AME	Ametek Inc/	55.40 Bn	36.26	7.29	2.18 Bn
8	ROK	Rockwell Automation, Inc	51.78 Bn	53.05	5.88	3.69 Bn

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2026)

Markets of customers [axis] Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2026)

Markets of customers [axis] Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password